Bionor Pharma
A privately held Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccines.
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 76.1m | 89.7m | 92.9m | - | 143m | 254m | 240m |
| % growth | - | 18 % | 4 % | - | - | 77 % | (5 %) |
| EBITDA | 9.9m | 11.7m | 20.4m | 26.4m | 13.5m | 25.9m | 16.0m |
| % EBITDA margin | 13 % | 13 % | 22 % | - | 9 % | 10 % | 7 % |
| Profit | 3.0m | 7.5m | 13.5m | 15.5m | 9.2m | 23.7m | 10.3m |
| % profit margin | 4 % | 8 % | 14 % | - | 6 % | 9 % | 4 % |
| EV / revenue | 3.2x | 2.4x | - | - | - | - | - |
| EV / EBITDA | 24.7x | 18.3x | - | - | - | - | - |
Source: Dealroom estimates
Related Content
Recent News about Bionor Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Bionor Pharma
Edit
ACQUISITION by Bionor Pharma Nov 2016